On September 24, 2024 Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy, reported that a scientific abstract submitted to the European Society of Cell and Gene Therapy (ESGCT) annual meeting 2024 has been selected for oral presentation (Press release, Circio, SEP 24, 2024, View Source [SID1234646834]). The presentation will be given by Circio´s CTO, Dr. Thomas B Hansen on 23 October 2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Circio´s unique and powerful circVec platform keeps building momentum, and we are very excited to be selected to present our technology at the prestigious ESGCT meeting." said Dr. Thomas B. Hansen, CTO of Circio "This meeting provides a great opportunity to showcase how the latest circVec generation continues to significantly outperform mRNA-based expression, thereby delivering a substantial improvement over current gold-standard gene therapy approaches."

The ESGCT invitation follows recent presentations at several RNA industry conferences and coverage in international life science media, highlighting the advantages and potential of circular RNA therapeutics and reinforcing Circio´s position as a leader in this rapidly emerging field.

Title of presentation:

Optimization of in vitro and in vivo performance of circVec, a vector-based circular RNA expression platform for enhanced gene therapy

Presenter:

Dr. Thomas B Hansen, CTO

Time and location:

23 October 2024 @ 19:30hrs CET – Rome, Italy